Reference
- Kubicki T, Gil L, Dytfeld D. Endoplasmic reticulum stress and proteasome inhibitors in multiple myeloma: room for improvement. Pol Arch Intern Med. 2021;131:361–368.
- Wang G, Fan F, Sun C, et al. Looking into endoplasmic reticulum stress: the Key to drug-resistance of multiple myeloma? Cancers (Basel). 2022;14(21):5340–5360. doi:10.3390/cancers14215340
- Bhatt P, Kloock C, Comenzo R. Relapsed/refractory multiple myeloma: a review of available therapies and clinical scenarios encountered in myeloma relapse. Curr Oncol. 2023;30(2):2322–2347. doi:10.3390/curroncol30020179
- Padilla J, Lee J. A novel therapeutic target, BACH1, regulates cancer metabolism. Cells. 2021;10(3):634–647. doi:10.3390/cells10030634
- Wiel C, Le Gal K, Ibrahim MX, et al. BACH1 stabilization by antioxidants stimulates lung cancer metastasis. Cell. 2019;178(2):330–345.e22. doi:10.1016/j.cell.2019.06.005
- Lignitto L, LeBoeuf SE, Homer H, et al. Nrf2 activation promotes lung cancer metastasis by inhibiting the degradation of Bach1. Cell. 2019;178(2):316–329.e18. doi:10.1016/j.cell.2019.06.003
- Chinese Hematology Association, Chinese Myeloma Committee-Chinese Hematology Association. The guidelines for the diagnosis and management of multiple myeloma in China (2020 revision). Chin J Intern Med. 2020;59(5):341–346.
- Mulligan G, Mitsiades C, Bryant B, et al. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood. 2007;109:3177–3188. doi:10.1182/blood-2006-09-044974
- Orlowski R, Stinchcombe T, Thomas E, et al. Phase I Trial of the Proteasome Inhibitor PS-341 in Patients with Refractory Hematologic Malignancies. J Clin Oncol. 2002;20(1):4420–4427. doi:10.1200/JCO.2002.01.133
- Field-Smith A, Morgan GJ, Davies FE Bortezomib (Velcadetrade mark) in the Treatment of Multiple Myeloma. Ther Clin Risk Manag. 2006;Sep2(3):271–9. doi:10.2147/tcrm.2006.2.3.271
- Richardson PG, Barlogie B, Berenson J, et al. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer. 2006;Mar 15; 106(6):1316–1319. doi:10.1002/cncr.21740
- Bhatnagar V, Gormley, Luo L, et al FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior Therapy. The Oncologist. 2017;22(11):1347–1353.
- Dimopoulos M A, Moreau P., Palumbo A, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. The Lancet Oncology. 2016;17(1):27–38. doi:10.1016/S1470-2045(15)00464-7
- Wallington-Beddoe C T, Mynott R L Prognostic and predictive biomarker developments in multiple myeloma. Journal of hematology & oncology. 2021;14:1–15. doi:10.1186/s13045-021-01162-7
- Lee J, Yesilkanal A E, Wynne J P., et al Effective breast cancer combination therapy targeting BACH1 and mitochondrial metabolism. Nature. 2019;568(7751):254–258. doi:10.1038/s41586-019-1005-x
- Liu Z, Wang J, Chen H, et al. Uncovering BTB and CNC homology1 (BACH1) as a novel cancer therapeutic target. Frontiers in Genetics. 2022;13:920911–920921. doi:10.3389/fgene.2022.920911
- Hu D, Zhang Z, , Luo X, et al. Transcription factor BACH1 in cancer: roles, mechanisms, and prospects for targeted therapy. Biomarker Research. 2024;12(1):21–44. doi:10.1186/s40364-024-00570-4
- Sato M, Matsumoto M, Saiki Y, et al. BACH1 promotes pancreatic cancer metastasis by repressing epithelial genes and enhancing epithelial–mesenchymal transition. CliCancer Research. 2020;80:1279–1292. doi:10.1158/0008-5472
- Davudian S, Mansoori B, Shajari N, et al. BACH1, the master regulator gene: A novel candidate target for cancer therapy. Gene. 2016;588:30–37. doi:10.1016/j.gene.2016.04.040